Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
about
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.Multiple Aspects of Gene Dysregulation in Huntington's DiseasePhysio-pathological roles of transglutaminase-catalyzed reactionsBeyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1Intron-exon swapping of transglutaminase mRNA and neuronal Tau aggregation in Alzheimer's diseasePossible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseasesCellular functions of tissue transglutaminaseTissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanismsTreatment of Mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure, and bacterial replication.Identification of two GTP-independent alternatively spliced forms of tissue transglutaminase in human leukocytes, vascular smooth muscle, and endothelial cells.Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin.Transglutaminase regulation of cell function.Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations.Tissue transglutaminase directly regulates adenylyl cyclase resulting in enhanced cAMP-response element-binding protein (CREB) activation.The selective vulnerability of nerve cells in Huntington's disease.Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptorsInhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.Type 2 transglutaminase in Huntington's disease: a double-edged sword with clinical potential.Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamineMitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.Two isoforms of tissue transglutaminase mediate opposing cellular fates.Huntington's Disease and Striatal Signaling.Experimental therapeutics in transgenic mouse models of Huntington's disease.Development of novel therapies for Huntington's disease: hope and challenge.Tissue transglutaminase crosslinks ataxin-1: possible role in SCA1 pathogenesis.Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.Therapeutics development for triplet repeat expansion diseases.Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregatesThe use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiationTransglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signalingThe Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability.Increased levels of gamma-glutamylamines in Huntington disease CSF.Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.Huntington's disease: progress and potential in the field.Neuroprotection for Huntington's disease: ready, set, slow
P2860
Q24548047-1B13933F-71FF-4BDE-BFE2-A46E50D59D9FQ24605880-DE5025E3-47D9-422D-86E8-F7932C4D481BQ24605961-AAC272DF-C881-4C60-ACFC-5B28F72C516FQ27008548-C63176E3-7EB7-4BB7-B8DD-697405258704Q28118540-E3F6CCDB-2533-4966-BABE-7EFCF051091DQ28248796-81CE8F98-3E10-4416-A181-5089BEA6CD5FQ28260600-F5F74614-3741-4CA2-A298-C44C12BC54BDQ28592026-4357F0EA-3027-4D59-81A0-FCB1B256B5D6Q30325785-5CECE6E3-B076-484D-BB3B-69B8D218E338Q33289840-8B8236EE-0178-4BC2-B94E-74B171E55DE6Q33536410-B4587339-124E-4C8C-BAEC-2D7A160A6DBCQ33588238-C38EB0EF-8518-47A3-AB92-2D59C0B21B8AQ33707936-1EF54407-D844-4CB9-BBFC-5E183DE47BDEQ33793353-9C103675-05A9-4BC6-B55F-C20FDA4E3ECEQ34077018-F4B597E1-1A11-4514-8BB6-09030F9F633BQ34081469-6E626FF0-7F7A-4698-A575-974F8FED904BQ34196409-9175E9F3-87ED-4077-B36F-C32A7BE915E5Q34216757-5364B929-EA44-4DB8-9ABE-EEF68C4E8F31Q34281322-ED21C471-210B-468A-ACE3-25436CB47B53Q34743269-4C550851-C64D-4FD9-83E8-19E2DA71DABAQ34763209-144BEE6E-E9D4-41E0-BA54-4D450F1558E3Q34775357-37A5B550-F4ED-4519-9B99-52BFEA8C259CQ34805750-853FFE55-E21D-4FEB-ADA8-090EF0B420AFQ34994779-31FBDF3C-CE1C-46E0-AC76-899FF15DC14DQ35157424-DC9FCBB0-2678-4042-AB24-85AD48F6D52FQ35286098-787CA9EC-C127-4EEE-8186-C2A57AAE0068Q35752429-37A1FFEB-37FB-4A8B-8216-7D9BF437FA5BQ36016932-D623A1DB-48A0-471F-B43F-2FC2492101A2Q36227615-0A0DC5D8-438B-47E1-B426-104D212E515FQ36241237-221C0D43-1B9A-4CBC-9ACC-226EF9BDD481Q36277195-CBC06335-693D-4ABE-83BA-843D99A11F3FQ36342395-A0993DD2-25DF-4E5F-BED0-D2DAC1897ACCQ36358871-22E2F6B1-A43F-47A0-BA93-864490878D45Q36711191-862061EC-14BE-4525-9058-C8A7433499FDQ36804922-7F9B73D5-51D7-42B3-A2F8-53296FC5E449Q36884822-BAE60C45-472E-4F4F-85DE-634B9740BA31Q36952919-8F1FAD01-8D5E-428E-9477-D5A6AD1EDB9DQ37001587-5BE83EDE-8042-463A-A660-44FF865A9983Q37016096-8AFF828B-CC1E-4B23-97F8-24307AAB4316Q37131243-4CA84206-3874-4DA6-8993-4924788ABCB6
P2860
Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Transglutaminase aggregates hu ...... ington's disease brain nuclei.
@ast
Transglutaminase aggregates hu ...... ington's disease brain nuclei.
@en
type
label
Transglutaminase aggregates hu ...... ington's disease brain nuclei.
@ast
Transglutaminase aggregates hu ...... ington's disease brain nuclei.
@en
prefLabel
Transglutaminase aggregates hu ...... ington's disease brain nuclei.
@ast
Transglutaminase aggregates hu ...... ington's disease brain nuclei.
@en
P2093
P2860
P356
P1476
Transglutaminase aggregates hu ...... ington's disease brain nuclei.
@en
P2093
P2860
P304
P356
10.1073/PNAS.96.13.7388
P407
P577
1999-06-01T00:00:00Z